ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$15.77M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$19.21M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $10.29M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$25.04M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$15.77M | (m) | $71.55M | (m) | $1.18M* | -$6.40M* | $20.16M | $19.15M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$19.21M | (m) | $70.87M | (m) | $796.00K | -$9.54M | $18.71M | $23.62M | (m) | (m) |
| 2025-09-30 | Reported | (m) | $10.29M | (m) | $93.97M | (m) | $409.00K* | -$7.13M* | $18.16M | $23.67M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$25.04M | (m) | $58.88M | (m) | $655.00K* | -$12.43M* | $18.00M | $24.13M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$29.60M | (m) | $52.44M | (m) | $1.26M | -$28.48M | $16.98M | $24.20M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$32.63M | (m) | $46.44M | (m) | $344.00K* | -$27.07M* | $16.67M | $24.16M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$47.32M | (m) | $43.19M | (m) | $1.73M* | -$17.30M* | $19.32M | $25.35M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$48.76M | (m) | $41.87M | (m) | $1.51M | -$38.35M | $18.05M | $30.25M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$50.96M | (m) | $37.92M | (m) | $2.78M* | -$46.68M* | $19.35M | $28.53M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$47.82M | (m) | $48.93M | (m) | $3.70M* | -$23.56M* | $17.91M | $32.24M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$57.19M | (m) | $37.65M | (m) | $2.92M | -$59.15M | $18.68M | $32.60M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$45.43M | (m) | $47.83M | (m) | $5.43M* | -$42.41M* | $14.91M | $35.66M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$52.50M | (m) | $43.66M | (m) | $5.30M* | -$47.06M* | $13.22M | $37.04M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$63.07M | (m) | $38.62M | (m) | $3.08M | -$64.45M | $13.19M | $37.84M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$56.33M | (m) | $39.47M | (m) | $14.62M* | -$43.44M* | $14.19M | $36.07M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$49.77M | (m) | $38.51M | (m) | $22.04M* | -$37.21M* | $10.77M | $37.80M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$41.28M | (m) | $38.44M | (m) | $15.84M | -$58.24M | $9.99M | $33.77M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$37.05M | (m) | $26.30M | (m) | $4.21M* | -$47.16M* | $6.05M | $30.31M | (m) | $688.00K |
| 2020-06-30 | Reported | (m) | -$36.91M | (m) | $20.99M | (m) | $2.26M* | -$31.08M* | $4.91M | $25.99M | (m) | -$1.48M |
| 2020-03-31 | Reported | (m) | -$34.62M | (m) | $20.91M | (m) | $2.96M | -$31.61M | $5.34M | $23.93M | (m) | -$323.00K |
| 2019-09-30 | Reported | (m) | -$18.05M | (m) | $26.06M | (m) | $3.43M* | -$30.14M* | $5.60M | $20.51M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$16.11M | (m) | $22.14M | (m) | $1.52M* | -$15.97M* | $5.73M | $16.53M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$20.05M | (m) | $12.67M | (m) | $3.83M | $278.30M | $4.99M | $12.48M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$9.16M | (m) | $17.19M | (m) | $2.19M* | -$11.69M* | $5.36M | $9.78M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$13.31M | (m) | $11.57M | (m) | (m) | (m) | $5.04M | $9.45M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$57.12M | (m) | $276.98M | (m) | $2.96M | -$45.99M | $71.36M | $93.77M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$162.55M | (m) | $178.96M | (m) | $3.66M | -$95.21M | $72.08M | $102.95M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$227.03M | (m) | $170.28M | (m) | $10.70M | -$156.32M | $75.55M | $122.12M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$200.19M | (m) | $185.31M | (m) | $16.35M | -$183.94M | $57.91M | $141.76M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$208.97M | (m) | $154.34M | (m) | $61.75M | -$192.73M | $49.30M | $142.34M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$152.82M | (m) | $98.38M | (m) | $18.80M | -$149.68M | $22.53M | $116.07M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$78.39M | (m) | $85.07M | (m) | $11.20M | $205.40M | $22.27M | $70.70M | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$49.76M | (m) | $55.66M | (m) | $6.30M | -$32.26M | $19.67M | $39.16M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$44.48M | (m) | $38.45M | (m) | $2.42M | -$34.86M | $15.68M | $32.00M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |